Tim Smith

This new data on younger acute sinusitis patients may indicate the value of testing for specific bacteria at the time of presentation in order to lower the use of antibiotics for this condition.

This new research examined trends among adults with severe and recurrent anaphylaxis, and identified several major risk factors.

This new research is the first to examine the use of the iMAP milk ladder in primary care settings for younger patients with IgE-mediated cow’s milk protein allergy.

This new data highlights the importance of enhancing social connection for older adults and identifying those at greater risk of nursing home entry.

This new research showed the value of physical exercise as well as training to help prevent cognitive declines, although the results had some inconsistencies.

In this interview with Dr. Baldwin, she spoke on her team’s recent research and its application to rosacea and other dermatologic conditions.

The long-awaited approval for VP-102 makes this treatment the first available therapy for the pox virus-borne skin disease.

New late-breaking trial data from the ADhere, Adjoin, ADvocate1, and ADvocate2 trials showed solid results for lebrikizumab in treating moderate-to-severe atopic dermatitis.

This new data could be valuable for follow-up appointments with patients who have cutaneous squamous cell carcinoma and for skin cancer services.

This new data on factors which may inhibit access to dermatologic care indicates the potential value for policy-makers as well as educators to make changes to fill such gaps in care.

This study indicates that interactions between genetic risk and lifestyle decisions among adults in China could allow for direction in prevention of early-stage dementia.

In his interview, Dr. Amin discusses his views on the FDA’s recent approval of ritlecitinib for the treatment of adolescent patients with alopecia areata.

For this segment of her interview, Dr. Mellerio further discussed the contents of her talk on new treatment options for epidermolysis bullosa, highlighting DEB and EB simplex.

In this interview segment, Dr. Mellerio spoke about the contents of her presentation titled ‘New Treatment Approaches for Epidermolysis Bullosa.’

This new data indicates that while it is not a physically limiting disease, alopecia areata can substantially affect patients’ lives on an individual and national level.

This new data highlights the need to address certain sociocultural, socioeconomic, and environmental factors that can more strongly affect individuals in minority groups.

The study’s findings bring major lessons for dermatologists to light, the most apparent of which being that many reasons for discordance between clinicians and patients may be modified.

These new findings may lead to a more accessible and rigorous approach to diagnosis, with a possibility of reduction of over-diagnosis.

This segment of her interview with HCPLive featured a discussion with Ferris on the FRONTIER 1 phase 2b trial results and their implications for psoriasis patients.

New phase 2b data from the FRONTIER 1 study showed promise for what could become the first and only oral IL-23 antagonist peptide for psoriasis.

While the unmet needs of patients of color is a growing concern in the dermatology world, more has to be done to address the obvious disparities in care.

This new data indicated the strong safety profile and efficacy of CAL/BDP-cream using PAD technology for psoriasis patients, and could lead to better adherence and outcomes in real-world settings.

New data indicates associations between conditions for pregnant mothers and offspring, though a connection to offspring food allergy was not evident in this research.

This systematic review and meta-analysis demonstrated the potential effectiveness of JAK inhibitors for alopecia, though further trials are needed for long-term use.

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

This new research highlighted the value of engaging Mohs surgery patients in shared decision-making to find the best pain control plan for their needs.

This new data demonstrated that hearing loss led to worse outcomes for older individuals, and fatigue assessments may be needed in the future to further capture fatigue’s multidimensionality.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for psoriasis patients.

Both biologic-naïve and biologic-experience patients saw benefits in the BRIGHT study examining therapeutic response to brodalumab over the course of 1 year.

New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.